CD73 inhibitors (CD73i) reverse the AMP/adenosine-mediated impairment of immune effector cell activation by immune checkpoint inhibitors (ICI)

被引：1
|
作者：
Becker, Annette [1 ]
Narasappa, Nell [1 ]
Yin, Fangfang [1 ]
Zhang, Kristen [1 ]
DiRenzo, Daniel [1 ]
Park, Timothy [1 ]
Kalisiak, Jaroslaw [1 ]
Lawson, Ken [1 ]
Jeffrey, Jenna [1 ]
Powers, Jay P. [1 ]
Schindler, Ulrike [1 ]
Walters, Matthew J. [1 ]
Tan, Joanne B. [1 ]
机构：
[1] Arcus Biosci, Hayward, CA USA
来源：
CANCER RESEARCH | 2018年 / 78卷 / 13期
关键词：
D O I：
10.1158/1538-7445.AM2018-710
中图分类号：
R73 [肿瘤学];
学科分类号：
100214 ;
摘要：
710
引用
收藏
页数：1
相关论文
共 50 条
  • [1] AB680, a potent and selective CD73 small molecule inhibitor, reverses the AMP/adenosine-mediated impairment of immune effector cell activation by immune checkpoint inhibitors
    Schindler, U.
    Becker, A.
    Lawson, K.
    Jin, L.
    Jeffrey, J.
    Kalisiak, J.
    Yin, F.
    Zhang, K.
    Chen, A.
    Swinarski, D.
    Walters, M. J.
    Young, S.
    Powers, J. P.
    Tan, J.
    EUROPEAN JOURNAL OF CANCER, 2018, 92 : S14 - S14
  • [2] Predictive value of CD73 expression for the efficacy of immune checkpoint inhibitors in NSCLC
    Ishii, Hidenobu
    Azuma, Koichi
    Kawahara, Akihiko
    Kinoshita, Takashi
    Matsuo, Norikazu
    Naito, Yoshiko
    Tokito, Takaaki
    Yamada, Kazuhiko
    Akiba, Jun
    Hoshino, Tomoaki
    THORACIC CANCER, 2020, 11 (04) : 950 - 955
  • [3] CD73: a new immune checkpoint for leukemia treatment
    Gao, Huan
    Zhang, Tingting
    Li, Ke
    Li, Xia
    FRONTIERS IN IMMUNOLOGY, 2025, 16
  • [4] The CD73 immune checkpoint promotes tumor cell metabolic fitness
    Allard, David
    Cousineau, Isabelle
    Ma, Eric H.
    Allard, Bertrand
    Bareche, Yacine
    Fleury, Hubert
    Stagg, John
    ELIFE, 2023, 12
  • [5] Identification of CD73 and A2AR/CD73 small molecule inhibitors for cancer immunotherapy as single agents or in combination with Immune-checkpoint therapies
    Fons, Pierre
    Bell, Andrew
    Esquerre, Michael
    Versluys, Stephanie
    Bertrand, Florie
    Schreyer, Adrian
    Hopkins-Navratilova, Iva
    Hernani, Leonardo-Silvestre
    Bergeaud, Celia
    Poussereau-Pomie, Celine
    Marchand, Ghislaine
    Robinson, Sean
    Culurgioni, Simone
    Cox, Richard
    Besnard, Jeremy
    Payne, Andrew
    Ray, Peter
    Pelissier, Emilie
    Paillasse, Michael
    Lisztwan, Joanna
    Johnstone, Craig
    Whittaker, Mark
    Hopkins, Andrew
    CANCER RESEARCH, 2019, 79 (13)
  • [6] Dual CD73 enzyme blocker to reverse immune suppression
    Yuan, Jijun
    CANCER RESEARCH, 2020, 80 (16)
  • [7] Adenosine and AMP gene expression profiles predict response to adenosine pathway therapies and indicate a need for dual blockade of CD73 and A2AR with CD73 inhibitors
    Willingham, Stephen
    Hotson, Drew
    Hsieh, Jessica
    Munneke, Brian
    Kwei, Long
    Buggy, Joseph
    Miller, Richard
    JOURNAL FOR IMMUNOTHERAPY OF CANCER, 2019, 7
  • [8] Bispecific antibody CD73xEGFR more selectively inhibits the CD73/adenosine immune checkpoint on cancer cells and concurrently counteracts pro-oncogenic activities of CD73 and EGFR
    Ploeg, Emily Maria
    Samplonius, Douwe Freerk
    Xiong, Xiao
    Ke, Xiurong
    Hendriks, Mark Alexander Johannes Martinus
    Britsch, Isabel
    van Wijngaarden, Anne Paulien
    Zhang, Hao
    Helfrich, Wijnand
    JOURNAL FOR IMMUNOTHERAPY OF CANCER, 2023, 11 (09)
  • [9] The impact of CD73 immune checkpoint blockade on procoagulant tissue factor
    Garrad, Evan
    Panicker, Sumith
    Moitra, Jaideep
    Kanthi, Yogen
    VASCULAR MEDICINE, 2023, 28 (05) : 506 - 506
  • [10] CD73 Is a Critical Immune Checkpoint in a Molecular Subtype of Pancreatic Cancer
    DelGiorno, Kathleen
    CANCER RESEARCH, 2023, 83 (07) : 977 - 978
12345